Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
Johnson & Johnson reported the first real-world data for its VARIPULSE Pro pulsed field ablation platform, showing 100% acute procedural success, a 0.4% primary adverse event rate, and a 17.9-minute mean ablation time across 225 patients at 19 European centers. Twelve-month Omny-IRE results for the investigational OMNYPULSE Platform showed 82.5% of 136 paroxysmal AF patients free from documented atrial arrhythmia recurrence under stringent monitoring, with all safety events resolved. A new Premier Database analysis also associated J&J's CARTO 3 mapping system with 31% lower risk of AF-related readmissions versus the competing EnSite system.
Key figures
- Omny ire centers
- 13
- Varipure centers
- 19
- Afeqt improvement
- 25.5-point
- Omny ire patients
- 136
- Varipure patients
- 225
- Varipure acute success
- 100%
- Omny ire adverse event rate
- 2.9%
- Varipure mean ablation time
- 17.9 minutes
- Varipure single catheter rate
- 88.9%
- Ensite readmission risk increase
- 31%
- Varipure primary adverse event rate
- 0.4%
- Omny ire 12m freedom from arrhythmia
- 82.5%
- Omny ire freedom standard monitoring
- 90.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.